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Abstract
Background: De novo inference of clinically relevant gene function relationships from tumor RNA-seq remains a
challenging task. Current methods typically either partition patient samples into a few subtypes or rely upon analysis
of pairwise gene correlations that will miss some groups in noisy data. Leveraging higher dimensional information can
be expected to increase the power to discern targetable pathways, but this is commonly thought to be an intractable
computational problem.
Methods: In this work we adapt a recently developed machine learning algorithm for sensitive detection of complex
gene relationships. The algorithm, CorEx, efficiently optimizes over multivariate mutual information and can be
iteratively applied to generate a hierarchy of relatively independent latent factors. The learned latent factors are used
to stratify patients for survival analysis with respect to both single factors and combinations. These analyses are
performed and interpreted in the context of biological function annotations and protein network interactions that
might be utilized to match patients to multiple therapies.
Results: Analysis of ovarian tumor RNA-seq samples demonstrates the algorithm’s power to infer well over one
hundred biologically interpretable gene cohorts, several times more than standard methods such as hierarchical
clustering and k-means. The CorEx factor hierarchy is also informative, with related but distinct gene clusters grouped
by upper nodes. Some latent factors correlate with patient survival, including one for a pathway connected with the
epithelial-mesenchymal transition in breast cancer that is regulated by a microRNA that modulates epigenetics.
Further, combinations of factors lead to a synergistic survival advantage in some cases.
Conclusions: In contrast to studies that attempt to partition patients into a small number of subtypes (typically 4 or
fewer) for treatment purposes, our approach utilizes subgroup information for combinatoric transcriptional
phenotyping. Considering only the 66 gene expression groups that are found to both have significant Gene Ontology
enrichment and are small enough to indicate specific drug targets implies a computational phenotype for ovarian
cancer that allows for 366 possible patient profiles, enabling truly personalized treatment. The findings here
demonstrate a new technique that sheds light on the complexity of gene expression dependencies in tumors and
could eventually enable the use of patient RNA-seq profiles for selection of personalized and effective cancer
treatments.
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Background
In recent years, innovations in high-throughput sequence-
based assays that allow for the rapid and cheap interro-
gation of the genomes and transcriptomes of individual
tumors have given rise to fresh hope for significant
progress toward understanding of complex cancer biology
and effective treatments [1]. Inference of clinically rele-
vant gene expression networks based upon RNA-seq pro-
files could provide crucial information in this context. The
tumor transcriptome has the potential to provide a view
of the functional network alterations that result from a
variety of causes, including genetic mutations, copy num-
ber variations, epigenetic states, the tumor microenviron-
ment, immunophenotype variations and even transient
dynamic effects. In principle, machine learning could be
used to leverage the rich information that gene expression
provides about each individual to infer tumor-specific
features that may guide treatment decisions. Unfortu-
nately, several challenges limit the usefulness of existing
methods. The data is high dimensional and the num-
ber of samples is small. For this reason, many methods
focus on simple linear, pairwise relationships, limiting
their generality. Clustering techniques typically use too
broad a brush, pigeon-holing patients into a small number
of clusters when understanding the interplay of multi-
ple independent factors is crucial. Finally, interpretability
of results is essential in this context in order to provide
insight into biological mechanisms that could motivate
new treatments.
To overcome these limitations, we apply a recently
developed machine learning algorithm, CorEx [2, 3], to
the analysis of RNA-seq transcriptomes. Multivariate and
nonlinear dependencies in the data are captured by total
correlation, a generalization of mutual information to
multiple variables. Intuitively, CorEx uses an optimization
scheme in order to efficiently infer latent variables that
explain as much of the dependence in the data as possi-
ble. Each latent factor discovered by CorEx is a function
of some possibly overlapping subset of the input variables,
i.e. genes, with high total multivariate information, and
reflects a relatively independent axis of variation in com-
parison to the other latent factors. Further, each latent fac-
tor defines a separate probabilistic clustering of samples,
and thus provides a factor-specific stratification of tumors
according to expression patterns of subgroups of genes
across the tumor samples. We can apply CorEx again to
these inferred latent factors to discover a hierarchy of
dependencies among genes.
Ovarian cancer is the deadliest gynecologic malignancy
due to its typically late stage at diagnosis, however it is
responsive to a wide variety of therapies. In addition to
the standard platinum/taxane combination for frontline,
active second line therapies include pegylated doxoru-
bicin, topoisomerase inhibitors, angiogenesis inhibitors,
anti-metabolites and PARP inhibitors [4, 5]. Ovarian can-
cer also appears to be an immunogenic tumor for which
checkpoint inhibitors, vaccines, and other immunothera-
pies may provide meaningful benefit [6–9]. Thus ovarian
cancer tumors can be expected to display a rich variety
of gene expression patterns related to outcomes under
various treatments. On the other hand, current second
line treatments are effective for less than 30% of patients,
are not curative, and come with often serious cumula-
tive toxicities. With the exception of DNA repair pathway
mutations for PARP inhibitors, there are no genetic mark-
ers currently in use to predict therapeutic response. Thus
new ways to match ovarian cancer patients to effective
therapies based upon individual tumor biology will likely
yield substantial gains in survival.
In this work we show how the use of CorEx to ana-
lyze ovarian cancer RNA-seq profiles uncovers relatively
small cohorts of genes that exhibit coherent patterns of
differential expression among tumors and that, in many
cases, these cohorts are associated with biological path-
ways as indicated by database annotations of the genes.
The lower levels of the hierarchy of inferred gene clus-
ters provide a parsing of the upper layer nodes with
respect to function. An example is a layer one node
that groups together regulatory noncoding RNAs to reg-
ulated protein coding elements. Patient stratification with
respect to individual gene groups shows differential sur-
vival associations in groups associated with known factors
in chemo-responsiveness. Evenmore significantly, stratifi-
cations based upon combinations of group factors display
synergistic survival associations. We highlight discovery
of a factor containing genes related to epigenetic con-
trol of stem cell characteristics that have not been pre-
viously observed in ovarian tumors. Additionally, when
breast cancer data not used for training is stratified rel-
ative to this latent factor, a survival association is also
observed. Finally, we compare the group results in ovar-
ian tumors to expression profiles in normal ovarian tissue
and demonstrate substantial differences in some cases.
The strong results presented here demonstrate a powerful
tool for dissecting therapeutically relevant gene expres-
sion relationships in tumor RNA-seq, and suggest it may
be usefully applied to infer complex correlation structure




The random variables, X1, . . . ,Xn, written as X for short,
represent measured gene expression values. Our goal is to
learn a small number of latent factors, Y = Y1, . . . ,Ym, so
that the Xi’s are (nearly) independent after conditioning
on Y. In other words, we are looking for latent factors that
explain the relationships in the gene expression data. Each
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latent factor will depend on some subset of the genes, and
it can take discrete values, Yj = 1, . . . , c, that correspond
to relative expression levels for that group of genes. We
found that stratifying each latent factor into three groups
was adequate for capturing relationships without caus-
ing problems with estimation. Therefore, our procedure
defines a clustering of genes associated with each Yj and,
for each group of genes, a stratification of patients into
three groups. Furthermore, this clustering procedure can
be iteratively applied to the latent factors, Y, themselves
to produce a hierarchical clustering of the genes. We now
review the technical approach for discovering the latent
factors and clusters (Fig 1).
We assume that the measured expression profile for
one patient corresponds to a sample, x, drawn from some
unknown distribution over the random variables (genes),
X, which is written as p(X = x). Similarly, we can write the
marginal probability for a single gene as p(Xi = xi). Mul-
tivariate mutual information, or total correlation (TC),
quantifies the amount of dependence among a set of vari-
ables [11]. Total correlation can be defined in terms of the
Kullback-Leibler divergence, DKL, or in terms of H, the












Intuitively, TC represents the distance between the true
distribution, and the distribution under the null hypoth-
esis that all variables are independent. TC is zero if and
only if the variables are all independent1. If we could enu-
merate all of the underlying causes of dependence in the
data, then the TC conditioned on these factors would be
exactly zero.
The recently introduced method of Total Correlation
Explanation (CorEx) is an information-theoretic opti-
mization that reconstructs latent factors that explain as
much of the dependence in the data as possible [2, 3]. The
principle behind CorEx is to search for a small set of latent
factors, Y = Y1, . . . ,Ym, so that the TC among the original
variables is minimized after conditioning on Y. We refer to
TC(X;Y ) = TC(X)−TC(X|Y ) as the correlation inX that
is explained by Y and we seek tomaximize this expression.
We would like to maximize TC(X;Y ) over all ways of
assigning discrete values to each Yj as a function of X. As
mentioned, we restrict Yj’s to take three possible values
so that, e.g., Yj = 0, 1, and 2 might correspond to rela-
tively low, neutral, and high expression. For each sample
of data, X = xl, with l = 1, . . . ,N indexing the samples,
we define a probability distribution over possible values
for each latent factor j, p(Yj = yj|X = xl). Surprisingly, the
optimization of TC(X;Y ) over all of these probability dis-
tributions is computationally efficient and has low sample
complexity [3]. We now describe the iterative procedure
for solving this optimization.
What makes our optimization tractable is that we can
write the solution for p(Yj = yj|X = x) in an ana-
lytic form that defines an iterative update scheme that is
guaranteed to converge to a local optimum. We begin at
iteration t = 0, with a random probability distribution,
pt=0(Yj = yj|X = xl), over each latent factor and for each
sample. The solution depends on two types of parameters.
First, αi,j are weights between zero and one that determine
how much Yj depends on Xi. Second, p(Xi = xi|Yj = c)
is the marginal probability of observing Xi = xi given
an observed label Yj = c. We take this distribution to
be a normal distribution with mean, μi,j,c and variance,
σi,j,c. The parameters, αi,j,μi,j,c, σi,j,c, along with the class
Fig. 1 A simple hierarchical model constructed by CorEx. Variables in each layer are associated with latent factors in the next higher layer with a
weight that is determined by optimizing over its relative contribution to the explanatory latent factors. Visually we set the thickness of links based
on mutual information between variables and the thickness of nodes is proportional to the information contributed by that factor toward the
objective, TC(X;Y)
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weights, can be updated at each time t according to the
following rules:
αt+1i,j = It(Xi;Yj|Y1, . . . ,Yj−1)/It(Xi;Yj) (2)














Yj = c|X = xl
)
xli














In practice, we alter the first rule to speed up compu-
tation and we devised a novel Bayesian estimate for the
last two update rules that improves results on datasets
with a small number of samples. Details of these revised
updates are described in Additional file 1: Supplementary
Methods.
The quality of the solution that is found by CorEx is
quantified through the expression TC(X;Y ). As we add
more latent factors this objective increases before achiev-
ing a peak and then decreasing. Because of computational
limitations, we used only 200 latent factors at the first
layer even though more would have resulted in higher TC.
At the higher levels, we tried different numbers of latent
factors to optimize TC(X;Y ) leading us to use 30 factors
at layer 2 and 8 at layer 3. With this number of factors,
each CorEx run took about two days on a single Amazon
“r3.xlarge” node with 30 GB of RAM.
As a clustering method, CorEx has been favorably com-
pared against standard methods like spectral clustering,
k-means, and hierarchical clustering [2]. CorEx can also
be viewed as a type of dimensionality reduction and
in that capacity has been compared to PCA, indepen-
dent component analysis, non-negative matrix factoriza-
tion, and Isomap [2]. More generally, CorEx represents a
new approach to unsupervised deep representation learn-
ing and, as such, is best compared to “neural network”
approaches like autoencoders and restricted Boltzmann
machines against which it has demonstrated the ability to
recover much more interpretable structure [3].
Training matrix data
Gene level RNA-seq values (normalized to reads per kilo-
base per million or RPKM) for 420 high grade serous
ovarian tumor samples and 780 breast cancer samples
were downloaded from the TCGA data portal (The TCGA
Research Network: http://cancergenome.nih.gov), along
with available clinical metadata for the samples. Somatic
mutation data for 316 samples was obtained separately
from the cBioPortal for Cancer Genomics [13, 14]. A
training set of genes was selected by combining the RPKM
data for the top 3000 genes by variance in expression with
the RPKM values for the 2371 genes that were mutated
in more than one sample. The gene RPKM values for the
selected genes were then converted to z-scores to form the
420x5371 training matrix Additional file 2. 376 samples
were associated with survival times in the clinical Biotab
file and used for the Cox proportional hazard analyses.
GTEx normal tissue data [15] for 39 samples was down-
loaded from the GTEx portal (www.gtexportal.org). For
the purposes of training on tumor and normal samples
together, expression values were converted to percentiles
within each sample to mitigate batch effects between the
TCGA and GTex projects.
Database annotations
KEGG, GO, and PPI enrichments for the gene groups
were obtained using the stringdb package in R [16, 17]. A
maximum of 400 genes were used from each group. For
groups from CorEx runs that utilized the Bayes shrink-
age prior, only genes with a weighted mutual information
greater than a threshold of 0.002 were retained for anno-
tation enrichment purposes. FDR values with respect to
the 200 groups (corresponding to the p-value cutoffs used
in the Circos [18] plot in Fig. 2) were calculated by ran-
dom selection from the set of 5371 genes used for training.
The genes were alloted to groups with a size distribution
identical to that of the CorEx discovered groups. In order
to obtain summary GO terms for upper layer nodes in
the CorEx factor hierarchy, the lists of GO terms from
stringdb were submitted to the Revigo web server [19],
which clusters GO terms to select a subset of distinct
representative terms. GO term information content was
approximated as −log(nd/nr) where nd denotes the num-
ber of descendants of the term in the gene ontology and
nr is the number of descents of the root term.
Clustering comparisons
Hierachical and k-means clustering as well as PCA analy-
sis were done using Cluster 3.0 [20]. Hierarchical cluster-
ing was performed using average linkage and a similarity
metric of absolute correlation on centered data vectors.
Discrete clusters were chosen by the cut method. PCA
clusters were formed by including genes with coefficients
greater then a threshold for each component such that the
resulting clusters had an average number of genes (actual
78) comparable to CorEx groupings. 200 clusters were
specified in all cases for comparison purposes.
Survival analysis
For survival analysis, the gene groups were filtered to
retain only those with fewer than 100 correlated genes in
each group above threshold significance and those associ-
ated with gene ontology terms with adjusted p-values less
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Fig. 2 Correlation Explanation algorithm applied to tumor RNA-seq. For training, CorEx is provided only a matrix of normalized gene expression
values for the available tumor samples. The number of possible labels for each latent factor is specified, here set to three. In this application, we also
set the number of layer one latent factors to 200. CorEx finds probabilistic assignments of genes to latent factors by maximizing the total correlation
of the genes in groups, simultaneously minimizing dependence between latent factor groups. The factor labels from lower layers are used as input
to upper layers in order to generate a hierarchical model. The output from CorEx is thus a hierarchical model, specified as a set of probabilities
characterizing the association of genes or factors with latent factors at the next highest layer as well as probabilities that a given tumor sample’s
expression pattern can be explained by each factor in a particular label state. The three probabilities for a given tumor sample and factor are can be
usefully summarized by a single value that is the natural logarithm of the probability difference for the factor labels corresponding to extremal
expression. The genes with high mutual information relative to latent factors show clear patterns of correlation when viewed on expression heat
maps with tumor samples ordered by the summary latent factor score
than a 1% FDR threshold. Additionally, fourteen groups
were eliminated that were presumed to represent chromo-
somal location correlations rather than network interac-
tions. This filtering resulted in 66 groups that were then
analyzed for single factor survival associations under a
coxphmodel in R. Patients were stratified according to rel-
ative risk under a predictive coxph model. Patients were
assigned to one of three groups according to whether
they were in the bottom 30%, top 30%, or middle 40% of
risk of death. The top individual factors with differences
in survival (determined by p-values between the two
extremal strata as calculated by the survdiff function less
than 0.05) were retained for combination analysis. The
false discovery rate for this procedure was estimated by
repeatedly selecting 66 factor groups (200 times), ran-
domly shuffling their factor labels with respect to patient
time of death and calculating p-values for both single and
combination factors in the same fashion as before. False
discovery rates were then calculated as the number of ran-
domized groups or combinations exhibiting p-values less
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than a given threshold divided by the observed number
of groups or combinations with p-values less than that
threshold.
Results
CorEx infers gene expression relationships from tumor
RNA-seq profiles
CorEx can be used to construct a hierarchy of latent
factors that “explain” correlated gene expression among
samples with respect to subsets of genes (Fig. 2). Details
of the algorithm and implementation can be found in the
“Methods” section and the references therein. In the con-
text of RNA-seq tumor profiles, the input to the algorithm
is a training matrix consisting of z-scores for each gene
among all the samples. The CorEx output is a set ofm gene
groups with the genes ordered within a group according
to their estimated mutual information (MI) with respect
to the group’s latent factor and a probabilistic assignment
of samples to the k factor labels. Thus for each sample j,
group i, and latent factor label k (here k ∈ {0, 1, 2}), CorEx
provides an estimate of P(Yi = k|Xj1,Xj2...Xjni), where Xjg
denotes the expression of gene g in the jth sample. Here
the P(Y = k|X1,X2...Xn) for each sample is converted to
a single score, fji that indicates sample j’s congruence with
the factor i label values representing either very high or
very low gene expression. This score provides an order-
ing of the samples with respect to gene expression. Heat
maps of genes within groups ordered by MI versus sam-
ples ordered by fji show how groups with the greatest
TC display strong correlations among many genes, with
the clearest relationships being between genes with high
group MI, whereas lower TC groups show noisier cor-
relations and/or few genes (Fig. 2 and Additional file 1:
Figure S1 of heat maps, and the Supplementary data files;
Additional files 3 and 4).
Sharing of genes among groups is an integral part of the
algorithm and this gene sharing is desirable for a couple
of reasons. For one, it known that gene products often
perform multiple roles within cells and therefore may
participate in multiple interaction networks. For another,
given that TC increases with the number of genes (all
other things being equal), it is easier for the algorithm
to find very small expression cohorts that participate in
larger networks when they can be manifested as similar
large network groups with different sub-clusters ranked
most highly. In this application, genes tend to be asso-
ciated with several groups on average, however typically
only one to four at relatively high MI values.
Due to the complexity of the search space, the same
gene groupings are not guaranteed to be found in dif-
ferent runs. However, comparison of gene lists between
runs demonstrates that groups with high TC per gene
are very likely to be reproduced. Additionally, we find
that a Bayes shrinkage prior over the factor probabilities
increases reproducibility of groups with low TC, at the
cost of possibly suppressing some real but weak signals
(Additional file 1: Figure S3). In this work we fix the num-
ber of latent factors in layer one to 200. Though this
may seem like a relatively large number, the vast major-
ity CorEx factors found appear to contain meaningful
correlations. This is evident from a comparison of the
group TC values to those resulting from training on a
randomly permuted expression matrix (Additional file 1:
Figure S4). The large TC values relative to the randomized
data strongly suggest that the discovered gene groups are
not merely the result of chance correlations in the data.
As one moves down the list of groups according to total
correlation, confidence in the clusters decreases though
there appear to be still biologically meaningful clusters at
the lower end, suggesting that training on a greater num-
ber of samples or taking into account additional biological
information will be useful. The latter is investigated in the
following sections.
CorEx gene groups are enriched for protein-protein
interactions, GO, and KEGG annotations
A majority of the CorEx gene groups show enrichment
for genes that function within specific biological path-
ways and/or networks as indicated by significant protein-
protein interactions (PPI), Gene Ontology terms [21], and
KEGG [22] pathway annotations (summarized in Fig. 3a).
Multiple groups are found related to the mitotic cell cycle
and its regulation, extracellular matrix organization and
interaction, chromatin modification and DNA packag-
ing, electron transport, and regulation of map kinase and
growth factor pathways, among others. Genes that code
for proteins that participate in larger functional complexes
such as ribosomes are also grouped together. Some of the
particular PPI graphs are shown in Fig. 3 where it can be
seen that CorEx finds networks of genes related to partic-
ular immune processes such as Type I interferon signaling,
antigen processing and presentation, immune cell acti-
vation, migration, and aggregation. In fact, a plurality of
found groups have predominantly immune system-related
annotations. Overall, the number of groups enriched for
annotations as well as their diversity and specificity sup-
port the usefulness of CorEx for parsing the information
about differentially activated biological processes from the
RNA-seq profiles at an unprecedented level of detail. (See
Additional file 1: Figure S2 and Supplementary data for all
interaction graphs and listing of terms.)
The CorEx groups often display especially clear PPI
enrichments with relatively little noise, though all three
types of annotations typically exceed threshold together.
Groups with greater total correlation are more likely to
yield significant database annotations. However, because
groups with high TC tend to be larger, groups with
somewhat lower TC tend have more specific functional
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Fig. 3 Gene Ontology, KEGG, and protein interaction enrichment for CorEx gene groups. a A circos plot indicates which latent factor groups of the
200 inferred by CorEx are enriched for genes on KEGG pathways (yellow), Gene Ontology terms (orange) and Protein-Protein interactions (blue). A
tick mark of the corresponding color is drawn for groups exhibiting enrichment greater than a threshold. Further, the blue PPI tick marks have
heights proportional to the relative enrichment (observed/expected). The group results appear in order of decreasing Total Correlation, with the
number of genes in a group indicated by the green shading on the outer ring of the circos plot. (darker means a greater number of genes with a
range from 4 to 1135) Cutoffs were initially chosen according to the presence of coherent biological signals, however randomization tests indicate
corresponding FDR values of 1%, 5%, and 10% for GO, KEGG, and PPI, respectively. The vast majority of CorEx groups show annotation enrichment,
typically for all three types. A sample of string network connections are shown on the outside, showing both a diversity of network function and
relatively few apparently spuriously associated genes within the groups. b Annotation enrichments of CorEx groups compared to standard
clustering methods including hierarchical clustering, k-means, and pca. Enrichment results are based upon 200 clusters for all methods
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annotations at low p-values. It can be seen that many
groups even with quite low TC sometimes have associated
annotations. Capturing these groups with relatively weak
signals that nonetheless appear biologically coherent was
part of the motivation for specifying such a large number
of factors. The database annotations offer some guidance
as to which may merit closer examination. While some
enrichment of annotations within the gene groups is not
surprising, CorEx substantially outperforms other meth-
ods such as hierarchical clustering, k-means, and principal
component analysis in terms of the percentage of gene
groups associated with significant biological annotations
(Fig. 3b).
Some of the power of CorEx in this context comes
from lifting the restriction of considering only pairwise
gene interactions, common in other approaches [23–25].
As a concrete example of the impact of this less restric-
tive inference method, one need only examine the pair-
wise relationships of the top ranked genes in one of the
CorEx groups, pictured in Fig. 4. The colors of the scat-
ter points indicate the CorEx label value for each tumor
sample. In the figure it is clearly evident that the top genes
have only weak pairwise expression correlations, yet the
clouds of similarly hued points remain coherent across the
various plots showing their higher dimensional correla-
tion. The corresponding expression heat map for group
106 (Additional file 1: Figure S1) also shows clearly that,
while any individual gene appears somewhat noisy, the
trend across the whole set is easily discernible. The full
set of genes from this group exhibit PPI enrichment as
well as significant enrichment for the KEGG pathways:
‘pathways in cancer’, ‘Wnt signaling pathway’, ‘ proteogly-
cans in cancer’, ‘basal cell carcinoma’, and ‘Hippo signaling
pathway’. CorEx detects this important set of expression
relationships that would almost certainly be overlooked
based upon pairwise correlations. Additionally, the sensi-
tivity for groups that exhibit stronger pairwise correlation
for the top genes can be increased when those signals are
reinforced with signals from lower-ranked genes exhibit-
ing weak pairwise correlations but high TC relative to the
group as a whole.
The CorEx hierarchy of factors has biological significance
The hierarchy of CorEx latent factors appears to reflect
biological organization on multiple levels. Though the
leaves in the CorEx tree have a great diversity of associ-
ated GO terms, those that are shared between children
and their common parent node display a trend toward
increased enrichment of higher level terms in the L2
cluster (Additional file 1). Some of these higher level func-
tional relationships are highlighted in Fig. 5. Clustering
of Gene Ontology terms in the groups reveal layer two
for immune signaling, extra-cellular matrix organization,
immune cell activation, mitotic cell cycle, microtubule-
related processes, and electron transport/chromosome
organization. While in some cases this is due to redun-
dancy of membership among the layer one gene groups
(though the genes are ranked differently within the
groups, the GO analysis here did not account for rel-
ative importance), in others there is a clear distinction
in gene membership and function on the finer scale.
For example, both groups 31 and 110 are incorporated
into the large immune-related cluster near the center of
Fig. 5a. However, these groups have both different associ-
ated GO annotations and zero genes in common. Group
31 has gene ontology terms associated with immune cell
activation (e.g. GO:45321 for genes EBI3, Cd79A, BATF,
FCER1G, CCL5, EOMES, CD3D, Cd7, LCP1, ZNF683,
Fig. 4 The use of multivariate mutual information increases the clustering power of CorEx. Pairwise correlations of normalized expression of
individual samples for the top genes in group 106 appear very weak. The factor label values (indicated by color) show strong coherence across the
different plots indicating how samples cluster more strongly in terms of total correlation
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Fig. 5 Gene function relationships in the latent factor hierarchy. a Hierarchical factor relationships are shown exhibiting a tendency to cluster layer
one groups with similar general Gene Ontology enrichments. Lines are shown connecting the top X strongest relationships and the top 1000 genes.
Thicker lines indicate higher CorEx relationship probabilities. Representative GO terms for hierarchically clustered groups only are shown in red.
Though this figure highlights clustering at layer one and above, many nonclustered layer one factors have very significant annotations as well,
detailed in Fig. 2 and the Additional file 1. b In addition to general relationships, specific causal relationships are also detected at the upper layers.
Here an example is shown in which noncoding RNAs that are implicated in tumor growth and metastasis via regulation of ribosome activity are
isolated in a layer zero group and joined at the higher level to ribosomal structure genes. Noncoding RNA functional annotations are taken from the
NCBI Gene database (http://www.ncbi.nlm.nih.gov/gene)
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CD2, ITK, THEMIS, B2M), adhesion (GO:7159 for genes
EBI3, RAC2, BATF, CCL5, EOMES, CD3D, Cd7, LCP1,
CD2, ITK, THEMIS, B2M ), and migration (GO:2687
for genes SELL, RAC2, CCL4, CXCL13, CCL5, CXCL11,
CXCL9, and CCL8). In contrast, group 110 primarily has
terms associated with inflammatory response (GO:6954
for genes IL4R,MEFV, TGFB1, NLRP3, SIGLEC1, C5AR1,
CD163, PIK3CG, NLRC4, TLR4, TNFRSF1B), apoptotic
process (GO: 6915 for genes TGFB1, HGF, ABR, C5AR1,
MKL1, NICAL1, MAP3K5, PIK3CG, INPP5D, NLRC4,
TRAF1, TLR4, TNFRSF1B), and cell death (GO:43067
for genes STK10, HGF, ABR, SIGLEC1, C5AR1, MKL1,
MICAL1, MAP3K5, PIK3CG, INPP5D, NLRC4, NCF2,
TRAF1, TLR4, JAK3). Thus higher level clusters such as
immune response are parsed at the first layer according to
specific biological sub-networks.
A particularly striking example of the kind of informa-
tion that can be gleaned from the layer two factors is
shown in Fig. 5b. One can see a layer two factor (node)
that joins four clusters of ribosomal proteins. The fifth
layer one cluster is comprised of a set of non-coding RNAs
related to cancer metastasis through regulation of growth
arrest and protein folding. Thus a cluster of non-coding
regulatory factors is linked to the downstream interac-
tions of proteins they influence. While the particular
information highlighted here is already known, the pres-
ence of these meaningful relationships suggest that novel
relationships can, in principle, be discovered by CorEx.
This is more likely to happen when many thousands of
samples are available to allow less common relationships
and perhaps even tumor-specific rewiring of interactions
to be seen.
We quantified the change in biological information con-
tent (IC) in the layers by calculating enriched GO term
IC as a function of layer level. The results are shown in
Fig. 6. Simply calculating the frequency distribution of IC
for different layers shows a relatively high frequency of low
information terms in the lower layer groups. However, if
one considers only GO terms that appear as significantly
enriched in both a child and its parent node, there is a
clear trend toward more significant enrichment of low IC
terms in the parent nodes. Increasing significance of low
IC terms in the parent nodes indicate an aggregation of
gene groups that reflect more specialized terms (hence
functional annotation) in the children.
Patient stratification based upon combinations of latent
factors yields differential survival associated with
tumor-activated pathways
The continuous labels for the CorEx latent factors can
be used as predictors of survival under a Cox propor-
tional hazard model [26, 27]. A subset of the CorEx small
to intermediate-sized gene groups was selected accord-
ing to known biological significance (Gene Ontology
enrichment) and used to stratify patients according to
relative risk of death under a Cox proportional hazard
model for the factor scores. We first constructed mod-
els for each factor individually. When this is done and
patients are stratified roughly into thirds according to
low, intermediate, and high relative risk of death, sev-
eral gene expression groups appear to be associated with
differential survival, as judged by the p-value for the dif-
ference between the two extremal Kaplan-Meier survival
curves (Fig. 7a and Additional file 1: Figure S5). False
discovery rates (FDRs) were also estimated by randomly
permuting the sample scores for each latent factor (shuf-
fling each column) in the score matrix. The top single
factor groups appear somewhat weak by this measure as
the values are strongly limited by the small number of
patient samples versus the number of potentially rele-
vant networks. Using this analysis, the top latent factor
group, related to immune chemokine and interferon sig-
naling, yields an FDR level close to .3. Genes with large
MI with respect to this group factor include among others
CXCL10, CXCL11, CXCL9, CXCL13, ISG20, GBP (1-5),
OASL, HERC5, STAT1, IFIT1, IFI35, TRIM22, and JAK2.
Other groups that exhibit survival associations encompass
additional immune system factors, fibroblast growth fac-
tor regulation, transforming growth factor beta signaling,
map kinase regulation,Wnt signaling, Jak-STAT signaling,
and cellular metabolism.
A perhaps even more compelling finding is that combi-
nations of these statistically weak factors yield increased
significance as pairs relative to a randomization test for
paired factors, with 16/21 combinations yielding FDRs
less than about .35 (Fig. 7b). This suggests synergy of indi-
vidual factors in terms of impact on survival. The pair of
factors that show the greatest association with survival is
immune system cytokine signaling combined with regu-
lation of the fibroblast growth factor pathway. These two
general features are hypothesized to be associated with
long term survival in ovarian cancer from other stud-
ies, the latter due to its relationship to chemo resistance
[28, 29]. The advantage here with respect to these pre-
viously known prognostic features is that each patient is
assigned a relative risk according to activation of related
pathways and therefore shows how they may combine
to influence survival, indicating patients who might ben-
efit from either single or simultaneous treatment with
immune system modulation or FGF pathway inhibitors.
Additionally, the fine parsing of overall immune sys-
tem function by the sub-networks present in different
groups has the potential to discriminate among differ-
ent immunotherapies in terms of likely efficacy on a
personalized basis. Overall, most of the top survival-
associated combinations involve immune-related factors,
emphasizing the primacy of the immunological milieu in
influencing ovarian cancer survival rates in this cohort
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Fig. 6 Comparison of term enrichment between parent and child clusters in the CorEx hierarchy. a The distributions of GO term information content
(IC) for all terms enriched in factor-defined gene groups show a relative overabundance of low information (lower specificity) terms for factors in the
lowest layer (L1). GO term IC is calculated as the negative logarithm of the ratio of the number of descendants of a given term in the Gene Otology
to the number of descendants of the root. b Relative enrichment of GO terms that are shared by child and parent nodes is compared by plotting
the difference of the (log) term enrichment p-values, with p1 referring to the p-value for the lower L1 layer and p2 referring to the p-value for the
upper L2 layer. A clear trend for increased enrichment of low information terms in parent nodes (L2), as one expects in a GO-like hierarchy
under the standard treatment protocols. The combina-
tion of a factor related to Wnt signaling and one for
fibroblast growth factor signaling also appears predictive
of survival in a subset of patients. Wnt signaling has also
been associated with clinical prognosis in ovarian cancer
[30]. Other factors and combinations of groups show nar-
rower survival differentials. We expect that some of these
play important roles for a relatively smaller proportion of
patients and will gain significance once a greater number
of tumor RNA-seq samples are available for analysis.
We performed survival analysis using PCA factors as
well. While CorEx and PCA appear comparable in terms
of the number of factors that can be used to stratify
patients according to survival, the number and quality of
biological enrichments for the CorEx factors is substan-
tially greater than that for PCA (Fig. 3b and Additional
file 1: Figure S7).
It should be emphasized that in this retrospective anal-
ysis of a patient cohort that was treated prior to 2010, we
are able to analyze the survival impact only with respect
to standard carbo/taxol therapies as no targeted therapies
were widely available or approved. Cell line and xenograft
experiments or analysis of tissues from other clinical tri-
als will likely bring to the fore other factor groupings
that are associated with response to recently approved or
experimental therapies, e.g. angiogenesis inhibitors, PARP
inhibitors, and apoptosis signaling modulators to name a
few [31–33].
CorEx discovers differential expression in ovarian tumors
of EMT-related genes previously implicated in breast
cancer stemness andmetastasis
A survival differential at longer times only is seen for
one CorEx gene expression factor (denoted G159). This
suggests that this factor may influence survival in a way
that is not related to initial carbo/taxol response per se.
Detailed examination of the Gene Ontology annotations
for this latent factor cluster revealed genes associated with
microRNAs in cancer (6 genes), chromatin modification
(8 genes), regulation of transcription from RNA pol II pro-
moter (10 genes), stem cell differentiation (5 genes), and
regulation of Wnt signaling (5 genes). Further, when this
factor is combined in a survival model along with the top
single factor within the same CorEx run (G103, immune
cytokine signaling), the resulting stratification yields a
more significant survival association than any other pair
of factors from that run (Fig. 8a).
Intrigued by the possibility of a factor related to some-
thing more general than response to a specific chemother-
apy, we sought to validate its significance using the TCGA
breast cancer data. The reasoning behind this was that
while breast tumors exhibit some similarity on a molec-
ular basis to ovarian tumors, there are also significant
differences. Earlier detection and a greater variety of
chemotherapeutic options means survival will depend
largely upon factors not directly related to carbo/taxol
response. We calculated factor scores for TCGA breast
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Fig. 7 Group survival association and combinations. a A Cox proportional hazard model is used to estimate relative risk for patients according to
individual factor label values. Using this model, a relative risk of death can be calculated for each patient based upon her group label value. When
patients are stratified into thirds according to relative risk, some factors show an association with survival indicated by the difference in Kaplan-Meier
survival curves for the extremal groups (p-values shown in the graphs). The figure shows survival curves for two such factors, G56 and G173. The
bottom 30%,middle 40%, and top 30% in terms of predicted survival under the coxph model are plotted inmagenta, blue, and red, respectively.
When these two factors are combined into a single risk model, the survival differential increases dramatically. b Single factor combinations with
various Gene Ontology annotations can be combined and show synergy relative to survival association. The false discovery rate under a
randomization test for six such pairs is below about 1/3 compared to only one single factor achieving that level. Note that it is not suggested that
factors be selected based solely upon survival associations but rather factors that are interesting for other reasons, e.g. they contain druggable
targets, can be investigated for an impact on survival both alone and in combinations
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Fig. 8 Discovery of new targets: regulatory microRNAs and EMT. a One factor was observed to show a bias toward a difference in long-term survival.
Though its survival differential was not significant alone, when put into a model combined with the factor for immune chemokine signaling, the
resulting survival association was substantially greater and exceeded that of every other tested pair for that run. b Breast cancer samples were
mapped to CorEx factors learned from ovarian tumors and demonstrate a survival difference for this factor. c The group contains a small network
related to microRNAs in cancer, chromatin modification, and stem cell differentiation. Work in breast cancer associates the network with a cellular
EMT phenotype and increased aggressiveness and metastasis of breast tumors. EMT features have been shown to be influenced through regulation
by TET3 of the demethylase DNMT3A and represent a potential for development of new therapies targeting the regulatory microRNA miR-22
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cancer tumor RNA-seq samples across the factors deter-
mined by the ovarian cancer training samples (i.e. we
did not train a new set of latent factors, but mapped the
breast cancer samples to the factors learned from ovar-
ian tumors). Using these scores to fit a stratified model
with respect to the G159 latent factor yields a survival
differential for the breast cancer patients (Fig. 8b). We
subsequently discovered that the genes in this group have
important functions within a network that was recently
studied by Song et al. [34] in preclinical models of breast
cancer, where it was shown that TET3 controls expression
of DNMT3A, a DNA methyl transferase that exerts spe-
cific influence on the chromatin state related to stemness
(Fig. 8c). Further, the network is implicated in the pro-
gression of breast cancer via the epithelial-mesenchymal
transition, invasion, and metastasis. Mesenchymal-like
properties of tumor cells and EMT-associated features
in general have been associated with poor prognoses in
ovarian cancer [35], though this particular network has
not been previously implicated. Importantly, this network
was shown to be controlled by a microRNA acting on
TET3, thus providing a novel target for drug development
[34]. Observation of this mechanism in ovarian cancer
tumors suggests not only a new biological driver for recur-
rence but also the possibility for selection of ovarian
cancer patients who might benefit from any experimen-
tal miR-22 modulators that may be developed for breast
cancer.
Some latent factors can be used to distinguish between
normal and cancerous ovarian tissue
We trained a CorEx factor model on RNA-seq profiles
from both normal and tumor ovarian tissue samples. In
order to mitigate differences due to experimental vari-
ations, the expression values in this case were replaced
with sample-relative percentiles [36]. The efficacy of this
approach can be seen in group heat maps that demon-
strate smooth variation in gene expression across tumor
and normal samples (Additional file 1: Figure S8). While
normal samples and similar tumors appear close to one
another in the heat maps, there is still sometimes a
qualitative difference that appears related to signal vari-
ance. Deeper exploration of the issues of cross-experiment
comparison for RNA-seq is beyond the scope of this work.
The trained factors show clear distinctions in gene
expression patterns between tumors and normal ovarian
tissue and these appear related to a variety of biological
processes including ones for development and regulation
of cell differentiation, neurogenesis, apoptosis, sex dif-
ferentiation, cell migration, and inflammatory response.
Histograms of the factor scores for a few representative
groups are shown in Fig. 9. These findings highlight some
commonalities of pathway dysregulation among ovar-
ian tumors. Further, several of the groups contain genes
that can be targeted with existing drugs [37, 38]. This
presents the possibility that repurposing of existing drugs
based upon this sort of data may provide new therapeutic
options for a great many ovarian cancer patients, though
the implications within these particular gene expression
cohorts need to be further elucidated.
Discussion
In cancer and other diseases, high-throughput data
combined with computational phenotyping i.e. the
algorithmic distillation of observables that explain and
allow prediction of the interaction of the course of dis-
ease and treatment, is poised to transformmedicine as we
know it. In this work we have presented a novel approach
toward the goal of an RNA-seq -based computational
phenotype. The method of correlation explanation lever-
ages multivariate mutual information to infer complex
hierarchical gene expression relationships directly from
RNA-seq transcription levels, and the groups of genes
thus obtained correspond to distinct cellular subnetworks
as indicated by Gene Ontology annotations and known
regulatory relationships. CorEx does this efficiently and
without requiring any form of prior knowledge. The hier-
archy of factors is shown to facilitate understanding and
interpretability by relating networks at multiple levels.
Though CorEx allows sharing of genes among groups, it
also attempts to maximize overall independence between
the groups in terms of expression patterns, with factors
at higher levels being progressively less dependent. This
leads to the ability to pick out groups from different upper
level factors that may combine synergistically, and this is
seen in the survival associations for some combinations
of factors. In addition, tumor-specific assessment of dif-
ferential transcriptional activation of the gene cohorts is
intrinsic to themethod. These results show how the obser-
vation of differential activity in these gene networks can
have great clinical impact by enabling selection of patients
most likely to benefit from particular therapies and/or
combinations of therapies.
The use of RNA-seq, rather than microarray data, is
essential for detailed inference of the transcriptional com-
putational phenotype due to its superior dynamic range,
sensitivity, and inherent whole transcriptome measure-
ment capability compared to microarrays. Many past
studies have focused on the use of microarray data, how-
ever RNA-seq should have substantial advantages for dis-
covery of cancer-specific network interactions and this is
supported by studies comparing the two [39, 40]. Some
genes in the expression cohorts found here are not even
measured in microarray experiments, often because their
function is inadequately characterized and thus don’t jus-
tify inclusion of corresponding microarray probes. Also,
uncommon transcript variants that arise from unstable
cancer genomes cannot be detected with microarrays,
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Fig. 9 Comparison to normal ovarian tissue suggests druggable targets. When normal ovarian samples are combined with ovarian tumors for
training, many factors capture differences in gene expression patterns between them. The histograms show factor scores in cases with large
differences that correspond to novel drug targets in ovarian cancer, some of which are listed below
resulting in misleading expression values. RNA-Seq data
captures the effects of such alterations in ways that
allow for their discovery and more accurate quantification
[41–43]. The results presented here from such a rela-
tively small patient cohort are extremely encouraging and
clearly show that it is possible to extract a great deal of
information from just a few hundred whole exome tumor
transcriptomes and makes a strong case for obtaining
larger numbers of samples in this context.
Early work on the clinical implications of large scale
gene expression data in cancer included direct correlation
of gene expression and responses of cell lines to cancer
agents [44]. More recently, gene co-expression analyses
based upon pairwise correlation or mutual information
have been applied to infer networks and regulatory mod-
ules [24, 45–47], some of which are associated with cancer
progression and prognosis. The number of modules found
e.g. in breast cancer is markedly fewer (10-20 in the cited
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studies). Regulatory module inference in these cases often
relies upon the application of graph theoretic techniques
such as maximal clique identification to identify densely
connected groups of genes, with special considerations to
allow overlaps. CorEx, in contrast, constructs a graph with
edges connecting multiple genes to latent factors rather
than to one another and overlaps are intrinsic to the infer-
ence process. An alternative approach is presented in [48]
wherein attractor metagenes are defined using mutual
information Though relatively more restrictive in many
ways and heuristic, this is similar in spirit to CorEx. Our
approach is most directly related to the information-based
clustering of [49]. CorEx represents a significant advance
over that work since the lower bound on total correla-
tion that CorEx uses for optimization makes multivariate
clustering computationally tractable for large numbers
of variables ([49] did not calculate TC for greater than
pairwise correlations). As far as we are aware, our work
with CorEx is the first successful use of full multivari-
ate mutual information in the context of high throughput
gene expression data. The principled approach of CorEx
and also the addition of data-guided smoothing via the
Bayes shrinkage prior allows for continuous improvement
as more data is generated. These properties combined
with favorable scaling suggest that CorEx can be widely
adopted to analyze and interpret complex gene expression
data in many contexts.
CorEx both provides a high level summary of the
content of groups of differentially expressed genes and
parses them out into particular groups for potential exper-
imental and therapeutic purposes. Therefore it is an
umbrella method that can encompass the particular find-
ings of other studies on specific prognostic features of
patient tumors. For instance, the original TCGA anal-
ysis of the ovarian tumor expression data used non-
negative matrix factorization to identify a partitioning
of genes and patients into a few subtypes [1]. Fea-
tures of the four subtypes are clearly reflected in some
of the higher level CorEx nodes such as that linking
immune response factors. In contrast, here the func-
tions broadly related to the putative subtypes have been
parsed more finely on the lower level to reveal spe-
cific tumor-activated pathways and druggable targets.
This allows one to make hypotheses regarding the inter-
action of functional gene modules in tumor develop-
ment and progression. Further, the impact of expression
modulation of such relatively smaller groups of genes
may be more easily tested in cell lines and xenograft
models.
There are many possible extensions and further appli-
cations of the methods described here. While mRNA
provides a functional readout of many different causal
processes, other types of salient information, e.g. somatic
mutations, copy number variation, or chromatin marks
related to gene activation or repression can be easily
correlated with the gene expression groups at the higher
level to directly link known biological causes to gene
expression cohorts. This information can then point
to specific mechanisms active in individual tumors or
strengthen the RNA insights with the integration of com-
plementary information. Though beyond the scope of
this initial work, pan-cancer analysis is obviously of great
interest, and CorEx’s favorable scaling behavior should
allow for straightforward application in that context.
Additionally, CorEx can be applied to other TCGA cancer
types alone where one is likely to see different networks
implicated.
Conclusions
We have demonstrated a new technique to detect and
comprehend the significance of coordinate gene expres-
sion in tumor subsamples. Due to the use of multivariate
information, the algorithm is exceptionally sensitive to
groups displaying multiple weak interactions. This prop-
erty enables the discovery of an unprecedented number
of functional biological expression groupings. In ovarian
cancer, where there is a particular need for tools to aid
in the development of both novel and rational combina-
tion therapies, we have shown that this method of analysis
discovers new targets and lends itself to the selection of
therapeutic combinations for individuals.
Endnote
1 “Total correlation” is a historical misnomer, since it is
not a measure of correlation, but of dependence.
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